Lucius LuciVande Vandetanib 300mg

Product Information

• Product name: LuciVande Vandetanib 300mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Vandetanib
• Current strength: 300mg
• SKU: LU-ITEM-13
• Site category: other cancer, thyroid cancer

Product Summary

LuciVande Vandetanib 300mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Vandetanib is the active ingredient used for this product page. Public prescribing information for Vandetanib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

Reference Indications

Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use Vandetanib in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of Vandetanib. Vandetanib is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use Vandetanib in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of Vandetanib.

Reference Dosage and Administration

Recommended dose of Vandetanib is 300 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

With this 300mg product, that corresponds to 1 x 300mg tablet when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH Vandetanib can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving Vandetanib. Do not use Vandetanib in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to Vandetanib administration. Monitor electrolytes periodically. Avoid drugs known to prolong the QT interval . WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH See for complete boxed warning. Vandetanib can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving Vandetanib. Do not use Vandetanib in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome.

Common Adverse Reactions and Monitoring

Patients with unresectable locally advanced or metastatic medullary thyroid cancer were treated with Vandetanib 300 mg (n=231) or Placebo (n=99). The population exposed to Vandetanib was 58% male, 94% white, and had a median age of 50 years. The data described below reflect a median exposure to Vandetanib for 607 days. The most commonly reported adverse drug reactions which occurred in >20% of Vandetanib-treated patients and with a between-arm difference of ≥5% included, in order of decreasing frequency: diarrhea/colitis, rash, acneiform dermatitis, hypertension, nausea, headache, upper respiratory tract infection, decreased appetite, and abdominal pain.

Drug Interactions and Special Populations

Avoid the use of strong CYP3A4 inducers because they may decrease Vandetanib exposure. Avoid the use of agents that prolong the QT interval. Avoid concomitant use of known strong CYP3A4 inducers during Vandetanib therapy. Avoid concomitant use of St. John’s wort because it can decrease vandetanib exposure unpredictably . Use caution and closely monitor for toxicities when administering Vandetanib with drugs that are transported by OCT2 . Use caution and closely monitor for toxicities when administering Vandetanib with digoxin . There are no available human data on Vandetanib use in pregnant women to inform a drug-associated risk. Vandetanib is embryotoxic, fetotoxic, and induced fetal malformations in rats at exposures less than or equal to those expected at the recommended human dose of 300 mg/day.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: CAPRELSA public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.